Drug intelligence / Profile preview

First Relief

Development stage
Unknown
Lead developer
AFT Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

First Relief is an over-the-counter (OTC) fixed-dose combination medication containing 500 mg of acetaminophen and 150 mg of ibuprofen per tablet. Developed by AFT Pharmaceuticals, it is indicated for the temporary relief of minor aches and pains associated with headaches, toothaches, backaches, menstrual cramps, muscular aches, and arthritis, as well as for the reduction of fever. The combination provides a multi-modal approach to analgesia; acetaminophen is thought to act primarily through central nervous system pathways to elevate the pain threshold, while ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), provides peripheral anti-inflammatory effects by inhibiting the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). This synergy allows for effective pain management at lower individual doses of each component, potentially reducing the risk of side effects associated with higher doses of either drug alone.

Brand names
First Relief
Other names
Maxigesicacetaminophen and ibuprofen tablets
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on First Relief.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on First Relief.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call